Get the Stockscreener App
1.86
30.07%
0.43
Pre-market:
1.98
0.12
+6.45%
Compass Therapeutics Inc stock is traded at $1.86, with a volume of 24.16M.
It is up +30.07% in the last 24 hours and up +12.73% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
See More
Previous Close:
$1.43
Open:
$1.6
24h Volume:
24.16M
Relative Volume:
29.32
Market Cap:
$255.92M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-5.3143
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
+32.86%
1M Performance:
+12.73%
6M Performance:
+114.78%
1Y Performance:
-3.63%
1-Day Range:
$1.52
$2.68
1-Week Range:
$1.425
$2.68
52-Week Range:
$0.765
$2.68
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.86 | 255.92M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Compass Therapeutics (NASDAQ:CMPX) Earns Buy Rating from HC Wainwright - Defense World
D. Boral Capital Reiterates “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX) - Defense World
Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by StockNews.com - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
Windtree Therapeutics Announces New Corporate Strategy in Recent Press Release - Defense World
KBW Regional Banking Index (KRX) QuotePress Release - The Globe and Mail
Nasdaq Financial 100 Index (IXF) QuotePress Release - The Globe and Mail
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate - GlobeNewswire
Another Day, Another Biotech Stealing The Show - MSN
Nasdaq Industrial Index (INDS) QuotePress Release - The Globe and Mail
Stock Market Movers Today • Top Gainers & Losers - Benzinga
CMPX stock touches 52-week high at $2.35 amid market fluctuations - Investing.com Canada
Compass Therapeutics' (CMPX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
D. Boral Capital Reaffirms "Buy" Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Compass Therapeutics reports progress on cancer treatments - Investing.com
US Penny Stocks To Watch In January 2025 - Simply Wall St
Geode Capital Management LLC Buys 128,655 Shares of FutureFuel Corp. (NYSE:FF) - Defense World
Golden Entertainment, Inc. (NASDAQ:GDEN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Geode Capital Management LLC Acquires 19,095 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Geode Capital Management LLC Lowers Stock Holdings in ON24, Inc. (NYSE:ONTF) - Defense World
Geode Capital Management LLC Raises Holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Tucows Inc. (NASDAQ:TCX) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Grows Stock Holdings in BARK, Inc. (NYSE:BARK) - Defense World
Geode Capital Management LLC Has $4.76 Million Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Geode Capital Management LLC Sells 8,363 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Geode Capital Management LLC Has $4.68 Million Stock Holdings in Medifast, Inc. (NYSE:MED) - Defense World
Geode Capital Management LLC Lowers Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Geode Capital Management LLC Buys 50,579 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Barclays PLC Buys 40,319 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Geode Capital Management LLC Acquires 718,411 Shares of Wheels Up Experience Inc. (NYSE:UP) - Defense World
Geode Capital Management LLC Raises Holdings in Nano-X Imaging Ltd. (NASDAQ:NNOX) - Defense World
Barclays PLC Has $269,000 Stock Position in Medifast, Inc. (NYSE:MED) - Defense World
Barclays PLC Boosts Stock Position in James River Group Holdings, Ltd. (NASDAQ:JRVR) - Defense World
Barclays PLC Has $234,000 Stock Holdings in CB Financial Services, Inc. (NASDAQ:CBFV) - Defense World
Barclays PLC Increases Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Grows By 44.8% - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $6.75 Average Price Target from Analysts - Defense World
D. Boral Capital Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - MSN
Compass Therapeutics (NASDAQ:CMPX) Now Covered by D. Boral Capital - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
D. Boral Capital Initiates Coverage on Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
Biliary Tract Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight - EIN News
Fmr LLC Increases Holdings in Invesco S&P MidCap Momentum ETF (NYSEARCA:XMMO) - Defense World
Bioventus (NYSE:BVS) Upgraded to “Neutral” at JPMorgan Chase & Co. - Defense World
Fmr LLC Trims Position in SPDR S&P 600 Small CapValue ETF (NYSEARCA:SLYV) - Defense World
Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Charles Schwab Investment Management Inc. Purchases New Stake in Ferrovial SE (NASDAQ:FER) - Defense World
The Manufacturers Life Insurance Company Purchases Shares of 13,221 Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Fmr LLC Acquires Shares of 38,361 Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):